Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →In a prospective multicenter cohort of 51 adults with newly diagnosed B-ALL, 10-color flow cytometry and NGS-based IGH testing showed 80.7% overall MRD concordance, while MRD positivity at three months—particularly by flow cytometry—predicted inferior relapse-free survival.
The study provides evidence that three-month MRD status can stratify relapse risk in adult B-ALL; it supports, but does not test, the inference that adapting therapy or transplantation decisions according to MRD—potentially using flow cytometry where NGS is unavailable—could improve outcomes.
In an observational 48-month extension involving 15 children from a prior randomized phase II trial, a 10-day course of topical murine nerve growth factor was followed by stable visual measures and MRI findings, but no evidence of persistent treatment efficacy relative to baseline or placebo.
The record supports long-term visual and neuroradiological stability after brief topical mNGF exposure, but not a durable treatment effect; it may be hypothesized that local NGF-mediated neuroprotection could help prevent OPG-associated visual loss, which requires confirmation in an adequately powered randomized trial.
In a 13-center retrospective cohort of 247 children with first-relapse AML, re-induction approaches were highly variable, no chemotherapy backbone showed a statistically significant comparative advantage, and gemtuzumab ozogamicin was associated with better remission and MRD-negative remission rates but not improved overall survival.
The observed response associations support prospective testing of gemtuzumab ozogamicin-containing re-induction and anthracycline addition to fludarabine/cytarabine-based therapy; however, any survival benefit is inferential and remains unproven by this retrospective study.
The study reports that sanguinarine analogue 25 inhibited U2OS and MG63 osteosarcoma cells and reduced cell-line-derived xenograft growth while inducing ROS-associated mitochondrial apoptosis and NRF2/GPX4-associated ferroptosis, with no reported liver or kidney toxicity in the mouse model.
The supplied evidence supports analogue 25 as a preclinical osteosarcoma lead that engages ROS-linked apoptosis and ferroptosis; it may offer greater activity and tolerability than sanguinarine, but this remains an inference requiring pharmacologic validation, broader osteosarcoma models, and human testing.
In a veterinary clinical trial of dogs with spontaneous osteosarcoma, histotripsy ablation was associated with local and systemic immune activation, while a subset treated before standard care survived beyond the reported historical median for canine disease.
The record provides evidence that histotripsy is followed by pro-inflammatory and adaptive immune signaling in canine osteosarcoma; it supports, but does not establish, the hypothesis that histotripsy could remodel the immunosuppressive tumor microenvironment and improve systemic or survival outcomes when combined with standard therapy in canine or pediatric osteosarcoma.
In a retrospective cohort of 14 children with spindle cell/sclerosing rhabdomyosarcoma, drug-sensitivity testing was feasible in all patients, identified uniform platinum sensitivity, and guided 13 patients with stable or progressive disease after VAC to platinum-containing regimens, after which all 13 had an objective response.
The reported evidence supports the feasibility of assay-guided treatment selection and an association between predicted platinum sensitivity and subsequent response; it remains an unproven hypothesis that this strategy improves survival or performs better than empiric platinum treatment.
In a prospective multicenter randomized noninferiority trial, 231 pediatric cancer febrile-neutropenia episodes classified as fever of unknown origin after favorable evolution at 48–72 hours had similar uneventful resolution with adjusted, narrower antimicrobial therapy versus maintained therapy (95% versus 96%).
The trial provides evidence that carefully selected, clinically improving pediatric cancer patients with febrile neutropenia and a negative infectious evaluation may undergo antimicrobial de-escalation without a detectable reduction in uneventful resolution; it is inferred, but not demonstrated by the reported results, that this strategy could reduce antimicrobial exposure, toxicity, and resistance.
This review synthesizes clinical-pharmacology considerations for pediatric cell and gene therapies, including first-in-human dosing, biodistribution, vector shedding, cellular expansion and persistence, preclinical modeling, and regulatory challenges.
The record supports the practical use of therapy-specific pharmacology frameworks in developing pediatric cell and gene therapies; it is reasonable—but inferential—to hypothesize that better dosing, kinetic monitoring, and preclinical-to-clinical translation could improve treatment selection and safety in pediatric oncology, including CAR-T-cell development.
This review evaluates polymeric, lipid-based, inorganic, hybrid, and exosome-based miRNA nanocarriers for osteosarcoma, comparing delivery characteristics and discussing barriers to targeting mineralized bone tumors and achieving clinical translation.
The supplied record supports that nanocarriers may address known delivery limitations of naked miRNAs; it remains an inference, rather than a demonstrated clinical result in this record, that tumor-targeted or stimuli-responsive miRNA delivery could reduce osteosarcoma metastasis or chemoresistance and improve treatment outcomes.
In a phase 1b/2 placebo-controlled trial, heterologous ChAdOx1-HPV/MVA-HPV vaccination was well tolerated and induced HPV-specific CD4+ and CD8+ T-cell responses but did not significantly improve high-risk HPV or cervical-lesion clearance.
The trial demonstrates that the two-vector vaccine can induce HPV-specific cellular immunity; it remains an unproven inference that optimizing dose, schedule, or participant selection—potentially informed by the reported high-dose clearance trend—could translate this immunity into clinically meaningful HPV or lesion clearance.
This meta-analysis of 10 randomized trials involving 536 pediatric oncology patients reports that virtual-reality distraction during needle-related procedures reduced reported pain, fear, anxiety, and distress and modestly shortened procedure duration, without significantly affecting heart rate.
Evidence from the included trials supports VR as a potentially effective nonpharmacologic distraction intervention for procedural symptom relief; it may improve the tolerability and efficiency of needle-related cancer care, but routine implementation remains an inference requiring larger multicenter trials and assessment of feasibility, safety, and durability.
In a randomized open-label phase 3 trial of 202 adults with core-binding factor AML, adding dasatinib to intensive chemotherapy and subsequent maintenance did not improve event-free or secondary survival outcomes, including in KIT-mutated disease, and increased serious adverse events.
The trial tested the hypothesis that inhibiting KIT-associated signaling with dasatinib would improve outcomes in CBF-AML; the supplied evidence does not support this regimen, although the negative result may inform avoidance of ineffective, toxicity-increasing treatment rather than establish a therapeutic benefit.
